The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
NATCO Pharma Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.00% INR985.00
America/New_York / 8 mai 2024 @ 06:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 176 423 mill |
| EPS: | 70.84 |
| P/E: | 13.90 |
| Earnings Date: | May 27, 2024 |
| SharesOutstanding: | 179.11 mill |
| Avg Daily Volume: | 1.055 mill |
| RATING 2024-05-08 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 13.90 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 13.90 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR338.26 (-65.66%) INR-646.74 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 951.92 - 1 018.08 ( +/- 3.36%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR985.00 (-1.00% ) |
| Volume | 1.074 mill |
| Avg. Vol. | 1.055 mill |
| % of Avg. Vol | 101.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NATCOPHARM.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NATCOPHARM.NS
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.